NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis $2.53 -0.08 (-3.07%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$2.57 +0.04 (+1.58%) As of 08/25/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About C4 Therapeutics Stock (NASDAQ:CCCC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get C4 Therapeutics alerts:Sign Up Key Stats Today's Range$2.50▼$2.6750-Day Range$1.40▼$2.8652-Week Range$1.09▼$7.22Volume544,478 shsAverage Volume1.63 million shsMarket Capitalization$180.06 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Read More C4 Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreCCCC MarketRank™: C4 Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 791st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingC4 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageC4 Therapeutics has received no research coverage in the past 90 days.Read more about C4 Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.52) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about C4 Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.17% of the float of C4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 14.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.17% of the float of C4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 14.50%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.73% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about C4 Therapeutics' insider trading history. Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CCCC Stock News HeadlinesCCCC Revenue Drops 46%August 12, 2025 | theglobeandmail.comC4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | globenewswire.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for. | Investors Alley (Ad)C4 Therapeutics: An Entry Point If There's Ever Going To Be OneJune 16, 2025 | seekingalpha.comC4 Therapeutics reports Q1 EPS (37c), consensus (42c)May 7, 2025 | msn.comC4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 7, 2025 | finanznachrichten.deC4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 7, 2025 | globenewswire.comC4 Therapeutics Inc. CCCC (U.S.: Nasdaq)May 1, 2025 | wsj.comSee More Headlines CCCC Stock Analysis - Frequently Asked Questions How have CCCC shares performed this year? C4 Therapeutics' stock was trading at $3.60 on January 1st, 2025. Since then, CCCC shares have decreased by 29.7% and is now trading at $2.53. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) released its earnings results on Thursday, August, 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.01. The business had revenue of $6.46 million for the quarter, compared to analyst estimates of $5.24 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 53.91% and a negative net margin of 325.88%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? C4 Therapeutics' top institutional shareholders include Wasatch Advisors LP (10.43%), Bank of America Corp DE (2.82%), Geode Capital Management LLC (1.05%) and Jane Street Group LLC (0.69%). View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of C4 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/07/2025Today8/26/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CCCC CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Price Target for C4 Therapeutics$8.00 High Price Target$12.00 Low Price Target$4.00 Potential Upside/Downside+216.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.32 million Net Margins-325.88% Pretax Margin-325.50% Return on Equity-53.91% Return on Assets-33.26% Debt Debt-to-Equity RatioN/A Current Ratio5.06 Quick Ratio5.06 Sales & Book Value Annual Sales$35.58 million Price / Sales5.06 Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book0.83Miscellaneous Outstanding Shares71,170,000Free Float64,958,000Market Cap$180.06 million OptionableOptionable Beta2.97 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:CCCC) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.